

Model for effective entrepreneur support and start-up formation

It takes an eco-system to build a venture

Reinhard Hiller, CEO Artisan Biomed

Sustainable Biotech Innovation Symposium

03 March 2020

www.artisanbiomed.co.za reinhard.hiller@artisanbiomed.co.za



ARTISAN BIOMED

The individual understood

- Brief background
- What is an innovation eco-system?
- Why do we need it?
- What should/could it look like?














Empowering the life & medical sciences in Africa

Centre for Proteomic & Genomic Research (CPGR)

Judith Hornby, PhD, MBA Managing Director (CPGR)

Judith.Hornby@cpgr.org.za

















noun ECOLOGY

a biological community of interacting organisms and their physical environment. "the marine ecosystem of the northern Gulf had suffered irreparable damage"









(in general use) a complex network or interconnected system.
 "Silicon Valley's entrepreneurial ecosystem"









HOW DOES IDIA DEFINE AN INNOVATION ECOSYSTEM?

An innovation ecosystem is made up of enabling policies and regulations, accessibility of finance, informed human capital, supportive markets, energy, transport and communications infrastructure, a culture supportive of innovation and entrepreneurship, and networking assets, which together support productive relationships between different actors and other parts of the ecosystem.


https://www.idiainnovation.org/ecosystem











https://masschallenge.org/article/startup-innovation-ecosystem-explained










CATEGORY ECOSYSTEM

A high-tech company is competing in the Smart City Internet of Things (IoT) category, and is interested in identifying niche players for potential partnerships. An innovation ecosystem mapping project reveals a number of potential partners.











- Complexity (stakeholders & components to consider)
- Inter-connectivity (relations, inter-dependencies)
- Systemic (difficult to control)
- Emergence (difficult to explain, but can to some extent predict)












- Only a small number of startups are successful. Some estimates suggest that 75 percent of venture-backed startups fail.
 The failure rate of all U.S. companies after five years may be over 50 percent, and over 70 percent after 10 years.
- Other sources cite that 30% of new businesses fail during the first two years of being open, 50% during the first five years and 66% during the first 10. Only 25% make it to 15 years or more.



https://www.entrepreneur.com/article/288769









- No market need
- 2. Ran out of cash
- 3. Not the right team
- 4. Got outcompeted
- 5. Pricing/cost issue
- 6. Poor product
- 7. Need/lack business model
- 8. Poor marketing
- 9. Ignore customers

- Lack of focus
- Lack of motivation, commitment and passion
- Too much pride, resulting in an unwillingness to see or listen
- Taking advice from the wrong people
- Lacking good mentorship
- Lack of general and domain-specific business knowledge: finance, operations, and marketing
- Raising too much money too soon

South Africa / Africa perspective

- Distance to other (major) locations (cost, time)
- Economic conditions (challenges, opportunities)
- Market readiness (are there customers?)












https://www.entrepreneur.com/article/288769

The world is complex and 'messy', has an effect on start-up endeavours








- CRISPR
- 3D printing
- AI


Exponential. tech

Economy



Environment

- Droughts
- Extreme weather
- Food security



Legal/regulatory



- Import regulations
- Sample transfer
- Data utilisation
- Education (HPCSA)
- Medicine regulations (SAHPRA)
- AI & AI (4IR) impact (automation)












What can a system look like?














Follows an iterative development approach (trial & error)...



- https://www.einfochips.com/blog/medical-device-design-guide-for-medtech/
- https://blog.innokasmedical.fi/blog/applying-design-thinking-lean-start-up-and-agile-methodologies-to-medical-device-design-and-development









DOMAIN	Core functions						
DIGITAL	Statistics	Bioinformatics	Data management		User needs	Product	
Funding & IP	IP	Knowledge transfer	Financing	management			Customer needs
SCIENCE	Basic & applied research	Education & training	Ethics	Quality ma			
WET LAB	Biological assays	Molecular assay	Sample management				









(1) Discovery & test validation

(A) Discovery

Candidate test developed on training set, followed by lockdown of all computational procedures




Confirmation of candidate omics-based test using:

- An independent sample set if available (preferred) OR
- 2. A subset of the training net NOT used during training (less preferred)

(B) Test validation

IRB approval & consultation with the FDA



Defined, validated, and locked down test (intended use, assay, computational procedures and interpretation criteria)

(2) Evaluation for Clinical Utility & Use

3 potential pathways (IRB approval & FDA consultation)

Prospective / retrospective study with archived specimens

No

Prospective clinical trial; test does NOT direct patient management

Prospective clinical trial; test **directs** patient management

IDE needed?

No


Yes

FDA approval / clearance or LDT process for Clinical Test

Additional high quality evidence to evaluate clinical utility of test

Practice guidelines & reimbursement

Clinical use




FDA, Food & Drug Administration; IDE, Investigational Device Exemption; LDT, Laboratory Developed Test; dotted box = CLIA Certified Laboratory; CLIA, Clinical Laboratory Improvement Amendments

Micheel, C. M., Nass, S. J., & Omenn, G. S. (Eds.). (2012). Evolution of translational omics: lessons learned and the path forward. National Academies Press.



How are we going to reach this goal (through integrating all the relevant parts)?














Supply of skilled human resources (technical)



CPGR, DIPLOMICS, other labs









Has a way to address these issues...

- 5000 sqm building
- Within range of current location, new building
- 1,200 to 1,500 sqm in space
- High-throughput laboratory in a novel innovation-supporting environment
- Aim is to achieve <u>co-location scenario</u> with other companies/organisations by the end of 2020
- Create a more vibrant innovation ecosystem, together with partners





For queries: reinhard.hiller@artisanbiomed.co.za











Model for effective entrepreneur support and start-up formation

It takes an eco-system to build a venture

Reinhard Hiller, CEO Artisan Biomed

Sustainable Biotech Innovation Symposium

03 March 2020

www.artisanbiomed.co.za reinhard.hiller@artisanbiomed.co.za



ARTISAN BIOMED

The individual understood